drugset
drugset / Trial / NCT04116840

Single Ascending Dose Trial to Evaluate the Safety, Tolerability, PK, and PD of MT1002 for Injection

NCT04116840 ↗

Phase 1 Completed 30 enrolled Shaanxi Micot Pharmaceutical Technology Co., Ltd.
NaSequentialOpen-labelTreatment

Summary

This is an open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single dose of MT1002 for injection following intravenous bolus/infusion ascending dose administration.

Timeline

Start
2019-04-29
Primary completion
2019-08-01
Completion
2019-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject MT1002 Peptide — Intravenous

Indications

No indication recorded.